|
References
1. Koutsky LA, Ault KA, Wheeler CM. A controlled trial of a human Papillomavirus type 16 vaccine. New Engl J Med 2002;347(21):1645-1651.
2. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human Papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 2004;364:1757-65.
3. Villa LL, Costa CA, Petta C, et al. Prophylactic quadrivalent human Papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled muticentre phase II efficacy trial. Lance Oncol 2005;6:271-8.
4. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human Papillomavirus 16/18 vaccine. J Nat Cancer Inst 2004;96(8):604-615.
5. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human Papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 2005;15:727-46.
|